Rational Design of RGD–Albumin Conjugates for Targeted Delivery of the VEGF‐R Kinase Inhibitor PTK787 to Angiogenic Endothelium
暂无分享,去创建一个
G. Kéri | G. Molema | R. Kok | L. Őrfi | K. Poelstra | M. Lacombe | R. Schaapveld | Kai Temming
[1] Damon L. Meyer,et al. Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels. , 2006, Bioconjugate chemistry.
[2] R. Tallarida,et al. An Overview of Drug Combination Analysis with Isobolograms , 2006, Journal of Pharmacology and Experimental Therapeutics.
[3] G. Kéri,et al. Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology. , 2006, Bioconjugate chemistry.
[4] S. Groshen,et al. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] G. Molema,et al. Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[6] Napoleone Ferrara,et al. Angiogenesis as a therapeutic target , 2005, Nature.
[7] G. Soff,et al. Update on angiogenesis inhibitors. , 2005, Current opinion in oncology.
[8] Eric Masson,et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Tetsuro Tanaka,et al. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). , 2004, International journal of pharmaceutics.
[10] P. Caliceti,et al. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. , 2003, Advanced drug delivery reviews.
[11] J. Berkhof,et al. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] G. Molema,et al. Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[13] H. Kozłowski,et al. Effect of cis-, trans-diamminedichloroplatinum(II) and DBP on human serum albumin. , 1999, Journal of inorganic biochemistry.
[14] P. Sadler,et al. Identification of platination sites on human serum transferrin using 13C and 15N NMR spectroscopy , 1999, JBIC Journal of Biological Inorganic Chemistry.
[15] Erkki Ruoslahti,et al. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule , 1984, Nature.
[16] R. Schiffelers,et al. New ways in RGD-peptide mediated drug targeting to angiogenic endothelium : On the nature of drugs, linkers, and carriers. , 2007 .
[17] R. Henning,et al. Chapter 6 Intracellular Delivery of the p 38 MAPK Inhibitor SB 202190 in Renal Tubular Cells : a Novel Strategy to Treat Renal Fibrosis , 2006 .
[18] Hans-Jü Rgen Wester. Molecular Targeting with Peptides or Peptide-Polymer Conjugates: Just a Question of Size? , 2005 .
[19] Grietje Molema,et al. Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics. , 2002, Bioconjugate chemistry.
[20] G. Molema,et al. Development of vasculature targeting strategies for the treatment of cancer and chronic inflammatory diseases. , 2002, Biotechnology annual review.